Please assess the completion status of the following clinical trial:

Trial Title: Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 50-85 years-old~* self-reported OAB symptoms for ≥3 months~* a mean of ≥8 micturitions/ 24 hr~* ≥3 urgency episodes/24 hr on a 3-day bladder diary~* at least some moderate problems on the Patient Perception of Bladder Condition (PPBC)~* Montreal cognitive assessment (MOCA) score ≥24~* Stable dose of dopaminergic medications and levodopa (between 300 and 1200 mg daily)~Exclusion Criteria:~* Urinary retention: PVR \>150 ml (as assessed by bladder scan)~* Contra-indications to fesoterodine~* Unwilling to stop current antimuscarinics~* Patients on anticholinergics for motor disturbances~* Dementia based on clinical evaluation~* Atypical Parkinsonian syndrome~* Deep brain stimulation~* Presence of hallucination

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
- Fesoterodine (Type: EXPERIMENTAL): Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).